Get the Stockscreener App
0.2138
25.32%
-0.0631
After Hours:
.23
0.0162
+7.58%
Clearmind Medicine Inc stock is traded at $0.2138, with a volume of 82.98M.
It is down -25.32% in the last 24 hours and down -78.41% over the past month.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
See More
Previous Close:
$0.2769
Open:
$0.3521
24h Volume:
82.98M
Relative Volume:
10.69
Market Cap:
$1.76M
Revenue:
-
Net Income/Loss:
$-6.78M
P/E Ratio:
-0.00501
EPS:
-42.6996
Net Cash Flow:
$-4.67M
1W Performance:
-54.90%
1M Performance:
-78.41%
6M Performance:
-79.11%
1Y Performance:
-84.45%
1-Day Range:
$0.20
$0.3975
1-Week Range:
$0.20
$0.649
52-Week Range:
$0.20
$2.18
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
0.2138 | 1.76M | 0 | -6.78M | -4.67M | -42.70 |
|
ARGX
Argen X Se Adr
|
918.60 | 57.24B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.51 | 110.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
201.62 | 42.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
363.80 | 41.68B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
725.87 | 74.02B | 14.25B | 4.58B | 3.88B | 41.77 |
Clearmind Medicine Inc Stock (CMND) Latest News
Will Clearmind Medicine Inc. stock keep outperforming rivals2025 Bull vs Bear & Risk Adjusted Buy and Sell Alerts - newser.com
Why Clearmind Medicine Inc. (CWY0) stock gets analyst attention2025 Market Trends & Detailed Earnings Play Alerts - newser.com
Can Clearmind Medicine Inc. (CWY0) stock survive global slowdownNew Guidance & Capital Efficiency Focused Strategies - newser.com
Will Clearmind Medicine Inc. stock reach all time highs in 2025July 2025 Closing Moves & Weekly Top Gainers Alerts - newser.com
Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder - Yahoo Finance
How Clearmind Medicine Inc. stock performs after earningsGold Moves & Safe Entry Zone Tips - newser.com
Is Clearmind Medicine Inc. (CWY0) stock inflation resilientPortfolio Value Report & Safe Swing Trade Setups - newser.com
Clearmind files patent for MEAI and PEA combination to treat depression - Investing.com Nigeria
Clearmind files patent for MEAI and PEA combination to treat depression By Investing.com - Investing.com South Africa
Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression - The Manila Times
Clearmind Medicine Inc. Files Israeli Patent Application for Innovative Depression Therapy Combining MEAI and PEA - Quiver Quantitative
Clearmind (Nasdaq: CMND) files Israeli patent for non-hallucinogenic MEAI depression drug - Stock Titan
Can Clearmind Medicine Inc. (CWY0) stock double in coming yearsRisk Management & Free Technical Confirmation Trade Alerts - newser.com
Is Clearmind Medicine Inc. stock positioned for long term growthJuly 2025 PostEarnings & Safe Entry Zone Tips - newser.com
Why Clearmind Medicine Inc. stock could benefit from AI revolution2025 Trade Ideas & High Win Rate Trade Tips - newser.com
Clearmind Medicine Inc CWY0 Stock Analysis and ForecastMarket Sentiment Report & Minimal Investment Portfolio Growth - earlytimes.in
Best data tools to analyze Clearmind Medicine Inc. stock2025 Market Overview & Technical Pattern Based Signals - newser.com
Is Clearmind Medicine Inc. stock supported by strong fundamentals2025 Key Lessons & Capital Efficiency Focused Strategies - newser.com
How sentiment analysis helps forecast Clearmind Medicine Inc.July 2025 WrapUp & Daily Volume Surge Signals - newser.com
Clearmind Medicine Inc Stock Analysis and ForecastDividend Reinvestment Plans & Invest Now – Opportunity Window Closing - earlytimes.in
Intraday pattern recognizer results for Clearmind Medicine Inc.Weekly Stock Report & High Accuracy Trade Alerts - newser.com
Clearmind Medicine receives approval for AUD clinical trial site By Investing.com - Investing.com Nigeria
Clearmind Medicine (CMND) Stock Soars Thursday: What's Going On? - Benzinga
Nasdaq Down Over 150 Points; Disney Shares Fall After Q4 Results - Benzinga
Clearmind Medicine stock soars after receiving final approval for AUD trial By Investing.com - Investing.com Nigeria
Clearmind Medicine stock soars after receiving final approval for AUD trial - Investing.com Nigeria
Clearmind Medicine receives approval for AUD clinical trial site - Investing.com
Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center - The Manila Times
Price momentum metrics for Clearmind Medicine Inc. explainedM&A Rumor & Safe Entry Point Identification - newser.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Volatility clustering patterns for Clearmind Medicine Inc.July 2025 Weekly Recap & Technical Analysis for Trade Confirmation - newser.com
Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment - The Manila Times
Clearmind Medicine Inc. Announces Patent Publication for Non-Hallucinogenic Depression Treatment in China - Quiver Quantitative
Clearmind (NASDAQ: CMND) receives CNIPA notice of MEAI depression patent publication - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Clearmind completes first patient cohort in AUD treatment trial By Investing.com - Investing.com Canada
Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder - The Manila Times
Clearmind completes first patient cohort in AUD treatment trial - Investing.com
Clearmind Medicine Inc. Advances CMND-100 Clinical Trial for Alcohol Use Disorder Treatment Targeting $20 Billion Market - Quiver Quantitative
Clearmind Medicine (NASDAQ: CMND) completes first AUD cohort; 6 patients treated - Stock Titan
What earnings margins imply for Clearmind Medicine Inc. (CWY0) stockMarket Volume Report & High Win Rate Trade Tips - newser.com
What momentum shifts mean for Clearmind Medicine Inc.Portfolio Update Summary & AI Powered Trade Plan Recommendations - newser.com
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.12%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):